Considerations for lung transplantation in patients with idiopathic pulmonary fibrosis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive and ultimately fatal disease. Currently, there is no proven effective therapy, and lung transplantation is the only intervention associated with prolonged survival. However, outcomes after lung transplantation are worse for IPF than for other frequent indications such as chronic obstructive pulmonary disease and cystic fibrosis. IPF is one of the most frequent indications for lung transplantation. Available lungs are a scarce resource; therefore, the selection criteria are very important to optimize outcomes after lung transplantation. The optimal procedure (single vs. bilateral lung transplantation) in IPF is not clear and should be determined on a case-by-case basis. IPF patients are often critically ill with advanced respiratory failure requiring high levels of support before transplant, and there are several technical surgical challenges specific to IPF. IPF patients have worse survival after lung transplant, at least in part due to early mortality, but it remains a mainstay of therapy given the lack of effective alternatives.

Original languageEnglish (US)
Pages (from-to)68-73
Number of pages6
JournalClinical Pulmonary Medicine
Volume22
Issue number2
DOIs
StatePublished - Mar 16 2015

Fingerprint

Idiopathic Pulmonary Fibrosis
Lung Transplantation
Transplants
Lung
Survival
Critical Illness
Cystic Fibrosis
Respiratory Insufficiency
Chronic Obstructive Pulmonary Disease
Patient Selection
Mortality
Therapeutics

Keywords

  • Bronchiolitis obliterans syndrome
  • Extra corporeal membrane oxygenation
  • Idiopathic pulmonary fibrosis
  • Lung transplantation
  • Primary graft dysfunction
  • Restrictive allograft dysfunction

Cite this

Considerations for lung transplantation in patients with idiopathic pulmonary fibrosis. / Perlman, David M.; Loor, Gabriel; Kim, Hyun J.; Tomic, Rade.

In: Clinical Pulmonary Medicine, Vol. 22, No. 2, 16.03.2015, p. 68-73.

Research output: Contribution to journalArticle

@article{4e790c2dd137416a8efe23400c85a982,
title = "Considerations for lung transplantation in patients with idiopathic pulmonary fibrosis",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a chronic progressive and ultimately fatal disease. Currently, there is no proven effective therapy, and lung transplantation is the only intervention associated with prolonged survival. However, outcomes after lung transplantation are worse for IPF than for other frequent indications such as chronic obstructive pulmonary disease and cystic fibrosis. IPF is one of the most frequent indications for lung transplantation. Available lungs are a scarce resource; therefore, the selection criteria are very important to optimize outcomes after lung transplantation. The optimal procedure (single vs. bilateral lung transplantation) in IPF is not clear and should be determined on a case-by-case basis. IPF patients are often critically ill with advanced respiratory failure requiring high levels of support before transplant, and there are several technical surgical challenges specific to IPF. IPF patients have worse survival after lung transplant, at least in part due to early mortality, but it remains a mainstay of therapy given the lack of effective alternatives.",
keywords = "Bronchiolitis obliterans syndrome, Extra corporeal membrane oxygenation, Idiopathic pulmonary fibrosis, Lung transplantation, Primary graft dysfunction, Restrictive allograft dysfunction",
author = "Perlman, {David M.} and Gabriel Loor and Kim, {Hyun J.} and Rade Tomic",
year = "2015",
month = "3",
day = "16",
doi = "10.1097/CPM.0000000000000083",
language = "English (US)",
volume = "22",
pages = "68--73",
journal = "Clinical Pulmonary Medicine",
issn = "1068-0640",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Considerations for lung transplantation in patients with idiopathic pulmonary fibrosis

AU - Perlman, David M.

AU - Loor, Gabriel

AU - Kim, Hyun J.

AU - Tomic, Rade

PY - 2015/3/16

Y1 - 2015/3/16

N2 - Idiopathic pulmonary fibrosis (IPF) is a chronic progressive and ultimately fatal disease. Currently, there is no proven effective therapy, and lung transplantation is the only intervention associated with prolonged survival. However, outcomes after lung transplantation are worse for IPF than for other frequent indications such as chronic obstructive pulmonary disease and cystic fibrosis. IPF is one of the most frequent indications for lung transplantation. Available lungs are a scarce resource; therefore, the selection criteria are very important to optimize outcomes after lung transplantation. The optimal procedure (single vs. bilateral lung transplantation) in IPF is not clear and should be determined on a case-by-case basis. IPF patients are often critically ill with advanced respiratory failure requiring high levels of support before transplant, and there are several technical surgical challenges specific to IPF. IPF patients have worse survival after lung transplant, at least in part due to early mortality, but it remains a mainstay of therapy given the lack of effective alternatives.

AB - Idiopathic pulmonary fibrosis (IPF) is a chronic progressive and ultimately fatal disease. Currently, there is no proven effective therapy, and lung transplantation is the only intervention associated with prolonged survival. However, outcomes after lung transplantation are worse for IPF than for other frequent indications such as chronic obstructive pulmonary disease and cystic fibrosis. IPF is one of the most frequent indications for lung transplantation. Available lungs are a scarce resource; therefore, the selection criteria are very important to optimize outcomes after lung transplantation. The optimal procedure (single vs. bilateral lung transplantation) in IPF is not clear and should be determined on a case-by-case basis. IPF patients are often critically ill with advanced respiratory failure requiring high levels of support before transplant, and there are several technical surgical challenges specific to IPF. IPF patients have worse survival after lung transplant, at least in part due to early mortality, but it remains a mainstay of therapy given the lack of effective alternatives.

KW - Bronchiolitis obliterans syndrome

KW - Extra corporeal membrane oxygenation

KW - Idiopathic pulmonary fibrosis

KW - Lung transplantation

KW - Primary graft dysfunction

KW - Restrictive allograft dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84924868918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924868918&partnerID=8YFLogxK

U2 - 10.1097/CPM.0000000000000083

DO - 10.1097/CPM.0000000000000083

M3 - Article

AN - SCOPUS:84924868918

VL - 22

SP - 68

EP - 73

JO - Clinical Pulmonary Medicine

JF - Clinical Pulmonary Medicine

SN - 1068-0640

IS - 2

ER -